Sep 27, 2022 4:10pm EDT iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update
May 12, 2022 4:05pm EDT iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update
May 09, 2022 8:00am EDT iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer
May 05, 2022 4:30pm EDT iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022
May 02, 2022 8:00am EDT iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants
